Compare Cloudflare Inc (NET) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cloudflare Inc vs TG Therapeutics Inc — how do they compare? Cloudflare Inc trades at $312.5 (market cap $101.23B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Cloudflare Inc is far larger — about 11.9× TG Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| NET | TGTX | |
|---|---|---|
Market Cap | $101.23B | $8.53B |
Sector | Technology | Health |
52-Week High | $330.74 | $59.06 |
52-Week Low | $160.16 | $26.94 |
Enterprise Value | $100.60B | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cloudflare (NET) trades at $284.41, up 1.97% with strong quarterly earnings beats and positive AI-driven momentum. The stock shows bullish moving averages but neutral oscillators, with key resistance at $292. Revenue growth remains robust at $2.17B for 2025, though profitability challenges persist with a -8.21% net margin. Recent partnerships with OpenAI and government security clearances provide significant growth catalysts.
Outlook remains positive with 72.5% analyst buy ratings and a $347.89 consensus target, representing 22% upside. Key risks include premium valuation (P/S 39.82), ongoing net losses, and competitive pressures in cybersecurity. The AI security positioning and federal contract potential offer substantial growth opportunities if execution succeeds.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cloudflare Inc
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
